Literature DB >> 16160079

Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells.

Muthusamy Kunnimalaiyaan1, Kelly Traeger, Herbert Chen.   

Abstract

Gastrointestinal (GI) carcinoid cells secrete multiple neuroendocrine (NE) markers and hormones including 5-hydroxytryptamine and chromogranin A. We were interested in determining whether activation of the Notch1 signal transduction pathway in carcinoid cells could modulate production of NE markers and hormones. Human pancreatic carcinoid cells (BON cells) were stably transduced with an estrogen-inducible Notch1 construct, creating BON-NIER cells. In the present study, we found that Notch1 is not detectable in human GI carcinoid tumor cells. The induction of Notch1 in human BON carcinoid cells led to high levels of functional Notch1, as measured by CBF-1 binding studies, resulting in activation of the Notch1 pathway. Similar to its developmental role in the GI tract, Notch1 pathway activation led to an increase in hairy enhancer of split 1 (HES-1) protein and a concomitant silencing of human Notch1/HES-1/achaete-scute homolog 1. Furthermore, Notch1 activation led to a significant reduction in NE markers. Most interestingly, activation of the Notch1 pathway caused a significant reduction in 5-hydroxytryptamine, an important bioactive hormone in carcinoid syndrome. In addition, persistent activation of the Notch1 pathway in BON cells led to a notable reduction in cellular proliferation. These results demonstrate that the Notch1 pathway, which plays a critical role in the differentiation of enteroendocrine cells, is highly conserved in the gut. Therefore, manipulation of the Notch1 signaling pathway may be useful for expanding the targets for therapeutic and palliative treatment of patients with carcinoid tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160079     DOI: 10.1152/ajpgi.00146.2005

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  49 in total

1.  A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.

Authors:  Tabraiz A Mohammed; Kyle D Holen; Renata Jaskula-Sztul; Daniel Mulkerin; Sam J Lubner; William R Schelman; Jens Eickhoff; Herbert Chen; Noelle K Loconte
Journal:  Oncologist       Date:  2011-05-31

2.  Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method.

Authors:  Scott N Pinchot; Renata Jaskula-Sztul; Li Ning; Noel R Peters; Mackenzie R Cook; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

Review 3.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

Review 4.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

5.  Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.

Authors:  David Yu Greenblatt; Max Cayo; Li Ning; Renata Jaskula-Sztul; Megan Haymart; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Gastrointest Surg       Date:  2007-09-15       Impact factor: 3.452

6.  Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.

Authors:  Li Ning; Renata Jaskula-Sztul; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-06-18       Impact factor: 5.344

7.  Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma.

Authors:  Max A Cayo; Ashley K Cayo; Sarah M Jarjour; Herbert Chen
Journal:  Am J Transl Res       Date:  2009-01-31       Impact factor: 4.060

8.  Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.

Authors:  Joel T Adler; Daniel G Hottinger; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

9.  MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.

Authors:  Jui-yu Chen; Mackenzie R Cook; Scott N Pinchot; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Surg Res       Date:  2010-01       Impact factor: 2.192

10.  Medullary thyroid carcinoma: targeted therapies and future directions.

Authors:  Scott N Pinchot; Muthusamy Kunnimalaiyaan; Rebecca S Sippel; Herbert Chen
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.